27 Sep
2023
16:30 E.S.T.

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Read more

07 Aug
2023
09:41 E.S.T.

Cellectis Provides Full Report for Second Quarter 2023 Financial Results

Read more

03 Aug
2023
12:52 E.S.T.

Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023

Read more

26 Jul
2023
09:47 E.S.T.

Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023

Read more

12 Jul
2023
10:29 E.S.T.

Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors

Read more

28 Jun
2023
10:33 E.S.T.

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023

Read more

08 Jun
2023
10:38 E.S.T.

Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023

Read more

05 Jun
2023
12:26 E.S.T.

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Read more

31 May
2023
16:18 E.S.T.

Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

Read more

24 May
2023
19:05 E.S.T.

Cellectis’ Annual Shareholders General Meeting to be Held on June 27, 2023

Read more